Piper Jaffray Downgrades Neothetics Inc. (NEOT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Wall St set for higher open after Micron revives AI optimism, upbeat economic data
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Needham & Company Downgrades Neothetics Inc. (NEOT) to Hold
December 15, 2015 7:20 AM ESTNeedham & Company downgraded Neothetics Inc. (NASDAQ: NEOT) from Buy to Hold after the company announced that its pivotal clinical program (consisting of studies AbCONTOUR-1 and -2) evaluating LIPO-202 for the reduction of central abdominal bulging did not meet the primary or any of the secondary... More
Neothetics (NEOT) Reports LIPO-202 Phase 3s Missed co-Primary, Secondary Endpoints
December 14, 2015 4:31 PM ESTNeothetics, Inc. (NASDAQ: NEOT) announced top-line results from its AbCONTOUR1 and AbCONTOUR2 U.S.-based pivotal Phase 3 trials to evaluate the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat. In both studies, LIPO-202 did not meet its co-primary composite and secondary endpoints. The co-primary endpoints were the proportion of subjects who reported an improvement of at least one point on the Patient-Global Abdominal Perception Scale (P-GAPS) and an improvement of at least two points on... More
